BioCentury
ARTICLE | Company News

Celgene sales and marketing update

October 17, 2016 7:00 AM UTC

The U.K.’s NICE issued updated draft guidance recommending the use of Otezla apremilast from Celgene to treat psoriatic arthritis in patients not responding to DMARD therapy or in patients where such therapy is not tolerated. The recommendation is contingent upon Celgene providing Otezla at an undisclosed discount under a patient access scheme. The agency, which focused its guidance on cost-effectiveness analyses, estimated the base-case incremental cost-effectiveness ratio (ICER) with the patient access scheme to be L39,052 ($48,456) saved per quality-adjusted life year (QALY) lost, which it considered a “cost-effective use of NHS resources.” ...